Pliant Therapeutics
PLRX
143 hedge funds and large institutions have $687M invested in Pliant Therapeutics in 2024 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 50 increasing their positions, 33 reducing their positions, and 19 closing their positions.
52% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 33
47% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 19
11% more call options, than puts
Call options by funds: $3.75M | Put options by funds: $3.37M
6% more funds holding
Funds holding: 135 → 143 (+8)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
2.3% less ownership
Funds ownership: 108.21% → 105.91% (-2.3%)
29% less capital invested
Capital invested by funds: $971M → $687M (-$284M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$10.1M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$8.29M |
| 3 |
BlackRock
New York
|
+$4.08M |
| 4 |
Morgan Stanley
New York
|
+$3.74M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$3.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$16.4M |
| 2 |
Capital International Investors
Los Angeles,
California
|
-$14.9M |
| 3 |
LCM
Laurion Capital Management
New York
|
-$12.6M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$6.6M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$5.53M |
PLRX Hedge Fund Activity: Q2 2024 in Review
143 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Pliant Therapeutics (PLRX) for Q2 2024, worth a combined $687M — down 29% from $971M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new PLRX positions and 19 closed out — a net gain of 9 holders — while 50 added to existing stakes and 33 trimmed.
The largest buyer was Great Point Partners, adding an estimated $10.1M. The largest seller was Citadel Advisors, cutting an estimated $16.4M.
- 143 institutional investors held Pliant Therapeutics (PLRX) as of Q2 2024, up from 135 in Q1 2024.
- Funds reported $687M of Pliant Therapeutics stock for Q2 2024, down 29% quarter-over-quarter.
- 28 funds opened new Pliant Therapeutics positions in Q2 2024 and 19 closed out, a net change of +9 holders.
- The largest Pliant Therapeutics buyer in Q2 2024 was Great Point Partners, an estimated $10.1M added.
- The largest Pliant Therapeutics seller in Q2 2024 was Citadel Advisors, an estimated $16.4M sold.
Based on aggregated 13F filings for Q2 2024.